Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Eli Lilly and Company
Merck Sharp & Dohme LLC
AbbVie
Astellas Pharma Inc
Amgen
AbbVie
Actuate Therapeutics Inc.
AstraZeneca
QuantumLeap Healthcare Collaborative
Revolution Medicines, Inc.
Hoffmann-La Roche
Norwegian University of Science and Technology
Gustave Roussy, Cancer Campus, Grand Paris
GlaxoSmithKline
Università Vita-Salute San Raffaele
University of Kentucky
Tesaro, Inc.
AbbVie
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Tesaro, Inc.
AbbVie
Sanofi
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute